168 related articles for article (PubMed ID: 27682513)
1. A definitive blood test for post-infectious irritable bowel syndrome?
Barlow GM; Rezaie A; Lin E; Pimentel M
Expert Rev Gastroenterol Hepatol; 2016 Nov; 10(11):1197-1199. PubMed ID: 27682513
[No Abstract] [Full Text] [Related]
2. Autoimmunity as a Potential Cause of Post-Infectious Gut Dysmotility: A Longitudinal Observation.
Rezaie A; Pimentel M; Cohen E
Am J Gastroenterol; 2017 Apr; 112(4):656-657. PubMed ID: 28381845
[No Abstract] [Full Text] [Related]
3. Assessment of Anti-vinculin and Anti-cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome.
Rezaie A; Park SC; Morales W; Marsh E; Lembo A; Kim JH; Weitsman S; Chua KS; Barlow GM; Pimentel M
Dig Dis Sci; 2017 Jun; 62(6):1480-1485. PubMed ID: 28451914
[TBL] [Abstract][Full Text] [Related]
4. Gut microbiota profiles and the role of anti-CdtB and anti-vinculin antibodies in patients with functional gastrointestinal disorders (FGID).
Vasapolli R; Schulz C; Schweden M; Casèn C; Kirubakaran GT; Kirste KH; Macke L; Link A; Schütte K; Malfertheiner P
Eur J Clin Invest; 2021 Dec; 51(12):e13666. PubMed ID: 34390492
[TBL] [Abstract][Full Text] [Related]
5. Diagnostics: Filling in the missing pieces.
Katsnelson A
Nature; 2016 May; 533(7603):S110-1. PubMed ID: 27191489
[No Abstract] [Full Text] [Related]
6. Immunization with cytolethal distending toxin B produces autoantibodies to vinculin and small bowel bacterial changes in a rat model of postinfectious irritable bowel syndrome.
Morales W; Triantafyllou K; Parodi G; Weitsman S; Park SC; Rezaie A; Pichetshote N; Lin E; Pimentel M
Neurogastroenterol Motil; 2020 Oct; 32(10):e13875. PubMed ID: 32436301
[TBL] [Abstract][Full Text] [Related]
7. Second-Generation Biomarker Testing for Irritable Bowel Syndrome Using Plasma Anti-CdtB and Anti-Vinculin Levels.
Morales W; Rezaie A; Barlow G; Pimentel M
Dig Dis Sci; 2019 Nov; 64(11):3115-3121. PubMed ID: 31152332
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects.
Pimentel M; Morales W; Rezaie A; Marsh E; Lembo A; Mirocha J; Leffler DA; Marsh Z; Weitsman S; Chua KS; Barlow GM; Bortey E; Forbes W; Yu A; Chang C
PLoS One; 2015; 10(5):e0126438. PubMed ID: 25970536
[TBL] [Abstract][Full Text] [Related]
9. Circulating Anti-cytolethal Distending Toxin B and Anti-vinculin Antibodies as Biomarkers in Community and Healthcare Populations With Functional Dyspepsia and Irritable Bowel Syndrome.
Talley NJ; Holtmann G; Walker MM; Burns G; Potter M; Shah A; Jones M; Koloski NA; Keely S
Clin Transl Gastroenterol; 2019 Jul; 10(7):e00064. PubMed ID: 31356481
[TBL] [Abstract][Full Text] [Related]
10. Autoimmunity Links Vinculin to the Pathophysiology of Chronic Functional Bowel Changes Following Campylobacter jejuni Infection in a Rat Model.
Pimentel M; Morales W; Pokkunuri V; Brikos C; Kim SM; Kim SE; Triantafyllou K; Weitsman S; Marsh Z; Marsh E; Chua KS; Srinivasan S; Barlow GM; Chang C
Dig Dis Sci; 2015 May; 60(5):1195-205. PubMed ID: 25424202
[TBL] [Abstract][Full Text] [Related]
11. [Gut Microbiota and Internal Diseases: Update Information. Topics: 1. The role of the gut microiota on inflammatory bowel disease (IBD)) and irritable bowel syndrome (IBS)].
Arai M; Matsuoka K; Kanai T
Nihon Naika Gakkai Zasshi; 2015 Jan; 104(1):35-41. PubMed ID: 26571772
[No Abstract] [Full Text] [Related]
12. Doing better with functional gastrointestinal disorders? Profiling gut microbiota and circulating antibodies to CdtB and vinculin.
Bonfrate L; Di Ciaula A; Portincasa P
Eur J Clin Invest; 2022 Jan; 52(1):e13702. PubMed ID: 34738648
[No Abstract] [Full Text] [Related]
13. The human translation of the postinfectious irritable bowel syndrome like rat model with antivinculin production after immunization with cytolethal distending toxin B.
Schmulson M; Davalos De la Rosa MF; Linares-Garcia L; Morales-Guzmán AS; Balbuena R; Lau C
Neurogastroenterol Motil; 2021 Jan; 33(1):e14042. PubMed ID: 33232542
[No Abstract] [Full Text] [Related]
14. Study of Antibodies to Cytolethal Distending Toxin B (CdtB) and Antibodies to Vinculin in Patients with Irritable Bowel Syndrome.
Zaki MES; Elhammady D; Foda Salama M; Abdelsalam M; Osman AOB
F1000Res; 2021; 10():303. PubMed ID: 34754418
[No Abstract] [Full Text] [Related]
15. Biomarkers as a diagnostic tool for irritable bowel syndrome: where are we?
Camilleri M; Halawi H; Oduyebo I
Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):303-316. PubMed ID: 28128666
[TBL] [Abstract][Full Text] [Related]
16. A 51-year-old with irritable bowel syndrome: test or treat for bacterial overgrowth?
Quigley EM
Clin Gastroenterol Hepatol; 2007 Oct; 5(10):1140-3. PubMed ID: 17916541
[No Abstract] [Full Text] [Related]
17. Role of environmental pollution in irritable bowel syndrome.
Marynowski M; Likońska A; Zatorski H; Fichna J
World J Gastroenterol; 2015 Oct; 21(40):11371-8. PubMed ID: 26523104
[TBL] [Abstract][Full Text] [Related]
18. Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture.
Gasbarrini A; Scarpellini E; Gabrielli M; Tortora A; Purchiaroni F; Ojetti V
Aliment Pharmacol Ther; 2011 Jun; 33(12):1378-9; author reply 1379-80. PubMed ID: 21569063
[No Abstract] [Full Text] [Related]
19. Is irritable bowel syndrome an infectious disease?
Thompson JR
World J Gastroenterol; 2016 Jan; 22(4):1331-4. PubMed ID: 26819502
[TBL] [Abstract][Full Text] [Related]
20. Visceral hypersensitive rats share common dysbiosis features with irritable bowel syndrome patients.
Zhou XY; Li M; Li X; Long X; Zuo XL; Hou XH; Cong YZ; Li YQ
World J Gastroenterol; 2016 Jun; 22(22):5211-27. PubMed ID: 27298564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
